The European healthcare technology and medical technology (MedTech) landscape in 2026 is characterised by a structural pivot from speculative, volume-driven growth toward a disciplined era of industrial maturity and strategic rationalisation. The result is a market divided into high-value, AI-enabled platforms commanding premium multiples and a vast swath of legacy hardware and diagnostics firms facing an existential crisis due to compliance costs and capital scarcity.